1. Exploring the Molecular Players behind the Potentiation of Chemotherapy Effects by Durvalumab in Lung Adenocarcinoma Cell Lines
    Marika Saar et al, 2023, Pharmaceutics CrossRef
  2. Fraisinib: a calixpyrrole derivative reducing A549 cell-derived NSCLC tumor in vivo acts as a ligand of the glycine-tRNA synthase, a new molecular target in oncology
    Iméne Ben Toumia et al, 2024, Front. Pharmacol. CrossRef
  3. Interaction between NSCLC Cells, CD8+ T-Cells and Immune Checkpoint Inhibitors Potentiates Coagulation and Promotes Metabolic Remodeling—New Cues on CAT-VTE
    Catarina Freitas-Dias et al, 2024, Cells CrossRef
  4. Lung Cancer in Estonia
    Tanel Laisaar et al, 2024, Journal of Thoracic Oncology CrossRef
  5. Editorial: Advances in novel pharmacotherapeutics and drug discovery: computational, experimental, translational, and clinical models
    Cristian Sandoval et al, 2024, Front. Pharmacol. CrossRef
  6. The Role of m6A Methylation in Tumor Immunity and Immune-Associated Disorder
    Siyu Mu et al, 2024, Biomolecules CrossRef